MCL1 and glioblastoma: Previous studies in colon cancers [36], rhabdomyosarcomas [37], lung cancers [38, 39], glioblastomas [40], and ovarian cancers [41] demonstrated that under conditions of cellular duress, including treatment with ABT-263, Mcl-1 protein levels are induced downstream of mTOR signaling.